Mutagenicity test systems for the detection of chromosome aberrations in vivo

Area of Science:

• Toxicology
• Genetics
• Pharmacology

Background:

• In vivo mammalian systems are preferred for pharmaceutical mutagenicity testing due to pharmacokinetic similarities to humans.
• Validated in vivo test systems for genetic endpoints are limited, with structural chromosome aberrations being a primary focus.
• Existing in vivo assays for chromosome aberrations vary in practicality and documentation.

Purpose of the Study:

• To provide an overview of current in vivo test systems for detecting chromosome aberrations.
• To emphasize the functions, advantages, and limitations of three key European Community-recommended tests.
• To discuss these tests based on practical experience.

Main Methods:

• Review of existing in vivo test systems for chromosome aberration detection.
• Detailed analysis of the metaphase analysis assay.
• Evaluation of the micronucleus test and the dominant lethal test as alternatives.

Main Results:

• The metaphase analysis assay, micronucleus test, and dominant lethal test are recommended by European Community guidelines.
• Each test possesses distinct functions, advantages, and limitations for in vivo mutagenicity assessment.
• Practical experience provides valuable insights into the application of these assays.

Conclusions:

• In vivo mammalian systems are crucial for accurate pharmaceutical mutagenicity testing.
• The metaphase analysis assay, micronucleus test, and dominant lethal test are key tools for evaluating chromosome aberrations.
• Understanding the strengths and weaknesses of each test is essential for effective risk assessment.